JNJ

238.09

+1.54%↑

UNH

267.77

-2.97%↓

TMO

554.31

-2.79%↓

ABT

109.12

+0.62%↑

ISRG

484.26

+1.76%↑

JNJ

238.09

+1.54%↑

UNH

267.77

-2.97%↓

TMO

554.31

-2.79%↓

ABT

109.12

+0.62%↑

ISRG

484.26

+1.76%↑

JNJ

238.09

+1.54%↑

UNH

267.77

-2.97%↓

TMO

554.31

-2.79%↓

ABT

109.12

+0.62%↑

ISRG

484.26

+1.76%↑

JNJ

238.09

+1.54%↑

UNH

267.77

-2.97%↓

TMO

554.31

-2.79%↓

ABT

109.12

+0.62%↑

ISRG

484.26

+1.76%↑

JNJ

238.09

+1.54%↑

UNH

267.77

-2.97%↓

TMO

554.31

-2.79%↓

ABT

109.12

+0.62%↑

ISRG

484.26

+1.76%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.09 -0.91

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.07

Max

1.1400000000000001

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+320.69% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	16M 142M
Eelmine avamishind	2
Eelmine sulgemishind	1.09

Uudiste sentiment

By Acuity

38%

62%

109 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. veebr 2026, 00:00 UTC

Kuumad aktsiad

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4. veebr 2026, 22:55 UTC

Tulu

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4. veebr 2026, 21:44 UTC

Tulu

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4. veebr 2026, 21:39 UTC

Tulu

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5. veebr 2026, 00:00 UTC

Tulu

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5. veebr 2026, 00:00 UTC

Tulu

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4. veebr 2026, 23:46 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4. veebr 2026, 23:45 UTC

Tulu

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4. veebr 2026, 23:32 UTC

Market Talk

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4. veebr 2026, 22:59 UTC

Omandamised, ülevõtmised, äriostud

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4. veebr 2026, 22:30 UTC

Tulu

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4. veebr 2026, 22:30 UTC

Tulu

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4. veebr 2026, 22:21 UTC

Tulu

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4. veebr 2026, 22:17 UTC

Market Talk

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4. veebr 2026, 22:15 UTC

Market Talk

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4. veebr 2026, 22:00 UTC

Market Talk

ESG Roundup: Market Talk

4. veebr 2026, 21:53 UTC

Tulu

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4. veebr 2026, 21:51 UTC

Tulu

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

4. veebr 2026, 21:50 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

4. veebr 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

4. veebr 2026, 21:45 UTC

Tulu

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4. veebr 2026, 21:44 UTC

Tulu

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4. veebr 2026, 21:43 UTC

Tulu

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4. veebr 2026, 21:41 UTC

Tulu

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4. veebr 2026, 21:36 UTC

Market Talk

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4. veebr 2026, 21:30 UTC

Tulu

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4. veebr 2026, 21:30 UTC

Tulu

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4. veebr 2026, 21:30 UTC

Tulu

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

320.69% tõus

12 kuu keskmine prognoos

Keskmine 4.88 USD 320.69%

Kõrge 8 USD

Madal 2 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

109 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.